INS and type 1 diabetes mellitus: Placebo-controlled clinical trials of pramlintide in type 1 diabetes [9–11] and type 2 diabetes [12–14] have shown that mealtime pramlintide injections as an adjunct to mealtime insulin significantly reduce glycated hemoglobin (HbA1c) levels (by 0.3–0.7 % and 0.3–1.0 %, respectively) and body weight (by 0.4–1.4 kg and 0.5–1.8 kg in type 1 and type 2 diabetes, respectively).